• About us
• Contact

Advertisement

Organisation › Details

Nextech Invest Ltd. (CH)

The global oncology specialist venture capital firm Nextech Invest Ltd., established in 1998 in Zurich, Switzerland, focuses on investing in cancer companies. Supported by a Scientific Advisory Board of seven oncologists chaired by Prof. Dr. David Livingston, Deputy Director Dana-Farber/Harvard Cancer Center, Nextech Invest is investing in emerging companies with pioneering innovations in cancer research that have compounds entering clinical trials. The other members of the Scientific Advisory Board are: Prof. Dr. Karl-Heinz Altmann, Prof. Dr. Glenn Dranoff, Prof. Dr. William Kaelin, Prof. Dr. Sir Bruce Ponder, Dr. Charles Sawyers and Prof. Dr. Paul Workman. Nextech Invest is a longstanding member of leading networks in private equity, such as EVCA, SECA and EVPA. Nextech Invest works closely with the Union for International Cancer Control (UICC). *

 

	Start	2011-04-28 renamed before
	Group	Nextech (Group)
	Predecessor	Nextech Venture L.P.
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Scheidegger, Alfred (Nextech Invest 201104 CEO + Founding Partner)
	Person 2	Schröder, Thilo (Nextech Invest 201607 Partner)
	Region	Zürich ZH
	Country	Switzerland
	Street	35 Scheuchzerstr.
	City	8006 Zürich ZH
	Tel	+41-44-366-6611
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Atavistik Bio Inc.. (8/24/21). "Press Release: Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer". Cambridge, MA.
		Record changed: 2024-03-26

Advertisement

More documents for Nextech (Group)

• [1] Exo Therapeutics, Inc.. (10/5/21). "Press Release: Exo Therapeutics Raises $78 Million Series B Financing". Cambridge, MA....
• [2] Hexagon Bio, Inc.. (9/22/21). "Press Release: Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes". Menlo Park, CA....
• [3] Biognosys AG. (5/19/21). "Press Release: Biognosys Announces the Appointment of Kristina Beeler as Chief Business Officer". Schlieren....
• [4] Boundless Bio, Inc.. (4/28/21). "Press Release: Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)". San Diego, CA....
• [5] MOMA Therapeutics. (4/15/20). "Press Release: MOMA Therapeutics – Drugging the Molecular Machines that Underlie Human Disease"....
• [6] Vividion Therapeutics, Inc.. (4/30/19). "Press Release: Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing". San Diego, CA....
• [7] Arrakis Therapeutics, Inc.. (4/18/19). "Press Release: Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA". Waltham, MA....
• [8] Revolution Medicines, Inc.. (4/24/18). "Press Release: Revolution Medicines Raises $56 Million in Series B Financing". Redwood City, CA....
• [9] Arvinas, LLC. (4/4/18). "Press Release: Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform". New Haven, CT....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.